$SLXP News If you're looking big pharma, look no

New Post Public Reply Private Reply Replies (0) Message Board

Dec 5, 2014 at 1:16 PM

$SLXP News

If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Drug companies Salix, Intercept reeling after earnings, drama 12:15 p.m. Nov. 7, 2014 - Russ Britt
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Sears leaps on REIT talk; First Solar drops on weak results 10:15 a.m. Nov. 7, 2014 - Sue Chang
Why eBay is like a divorcee, and a pharma pick that’s setting up for a pop 8:45 a.m. Nov. 7, 2014 - Shawn Langlois
Disney’s stock slides as quarterly earnings lack magic 7:04 p.m. Nov. 6, 2014 - Sue Chang
Salix Pharma shares fall on disappointing outlook, CFO resignation 6:54 p.m. Nov. 6, 2014 - Wallace Witkowski
Scuttled ‘inversion’ deals pile up in wake of Treasury rules 3:14 p.m. Oct. 27, 2014 - Robert Schroeder
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
RadioShack gets a jolt from financing report; Mylan rises 8:22 a.m. Oct. 3, 2014 - Sue Chang
Salix shares jump 5.9% premarket as merger plan is cancelled 7:14 a.m. Oct. 3, 2014 - Silvia Ascarelli
What could scare markets over upcoming earnings, and Buffett’s onto something 6:09 a.m. Oct. 3, 2014 - Barbara Kollmeyer
Salix, Cosmo cancel merger amid inversion crackdown 3:44 a.m. Oct. 3, 2014 - Chip Cummins
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
T. Rowe Price urges Allergan to drop Salix bid 3:38 p.m. Sept. 26, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Pershing threatens to sue Allergan if no holder vote held on Salix deal 8:28 a.m. Sept. 23, 2014 - David Benoit
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff

Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Sterne Agee Says Salix Pharmaceuticals Accounting Concerns Are 'Overdone' 8:09 a.m. Dec. 2, 2014 - benzinga.com
Salix Plans to Boost Size of Board 5:16 p.m. Nov. 24, 2014 - The Wall Street Journal Interactive Edition
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews 1:00 a.m. Nov. 19, 2014 - Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook 1:00 a.m. Nov. 19, 2014 - Zacks.com
Actavis to Buy Allergan for $66 Billion 7:24 p.m. Nov. 17, 2014 - The Wall Street Journal Interactive Edition
The 3 Best ETFs for Mid-Cap Growth 5:50 a.m. Nov. 17, 2014 - InvestorPlace.com
Actavis Nears Deal to Acquire Allergan 7:23 p.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Expect More Specialty Pharma Deals 7:40 a.m. Nov. 14, 2014 - Barrons.com
Hottest Healthcare Stocks Now – NXTM NPSP SLXP VAR 12:15 p.m. Nov. 13, 2014 - InvestorPlace.com
Top Analyst Upgrades and Downgrades: Comcast, Groupon, HCA, J.P. Morgan, JetBlue, NetApp, Verifone and More 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Actavis Says 'Let's Make A Deal' 9:42 a.m. Nov. 11, 2014 - Seeking Alpha
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog 2:56 p.m. Nov. 10, 2014 - Zacks.com
Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection 10:28 a.m. Nov. 10, 2014 - Seeking Alpha
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock 9:51 a.m. Nov. 10, 2014 - TheStreet.com
Salix Pharmaceuticals (SLXP) Downgraded From Buy to Hold 9:35 a.m. Nov. 10, 2014 - TheStreet.com
Deutsche Bank Slashes Price Target On Salix Pharmaceuticals 9:04 a.m. Nov. 10, 2014 - benzinga.com
Salix Pharmaceuticals, Ltd. (SLXP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 10, 2014 - Zacks.com
Biggest Movers in Healthcare Stocks Now – DVAX ACHN BMRN SLXP 6:30 a.m. Nov. 10, 2014 - InvestorPlace.com
'Fast Money' Recap: When Is the Best Time to Buy Twitter Stock? 5:00 a.m. Nov. 8, 2014 - TheStreet.com

SLXP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP 12:35 p.m. Dec. 2, 2014 - PR Newswire - PRF
Hagens Berman Reminds Investors of January 6th Lead Plaintiff Deadline in Suit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) 8:30 a.m. Dec. 1, 2014 - GlobeNewswire
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Salix Pharmaceuticals, Ltd. - SLXP 5:01 p.m. Nov. 25, 2014 - GlobeNewswire
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors 10:57 a.m. Nov. 25, 2014 - BusinessWire - BZX
Salix Pharmaceuticals Announces Plan to Augment Board of Directors 4:01 p.m. Nov. 24, 2014 - BusinessWire - BZX
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP 3:20 p.m. Nov. 24, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit 9:34 p.m. Nov. 19, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP 8:52 p.m. Nov. 13, 2014 - GlobeNewswire
Lieff Cabraser Announces Class Action Litigation Against Salix Pharmaceuticals, Inc. - SLXP 3:05 p.m. Nov. 13, 2014 - BusinessWire - BZX
Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders According to a Recently Filed Class Action 7:06 p.m. Nov. 12, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceuticals Ltd and Certain Officers -- SLXP 6:22 p.m. Nov. 12, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of $250,000 or More Are Encouraged to Contact Glancy Binkow & Goldberg LLP 12:32 p.m. Nov. 12, 2014 - BusinessWire - BZX
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd. 12:10 p.m. Nov. 11, 2014 - PR Newswire - PRF
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk 9:05 a.m. Nov. 11, 2014 - PR Newswire - PRF
SALIX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Salix Pharmaceuticals Ltd. - SLXP 10:00 p.m. Nov. 10, 2014 - GlobeNewswire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals, Ltd. 5:27 p.m. Nov. 10, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP 4:04 p.m. Nov. 10, 2014 - GlobeNewswire
Wolf Popper LLP Announces Investigation on Behalf of Investors in Salix Pharmaceuticals Ltd. 12:09 p.m. Nov. 10, 2014 - PR Newswire - PRF
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. -- SLXP 11:40 a.m. Nov. 10, 2014 - GlobeNewswire
Deadline in Lawsuit for Investors in Salix Pharmaceuticals, Ltd. (SLXP) Shares Announced by Shareholders Foundation 9:30 a.m. Nov. 10, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SPECS Framework: Rethinking Career Growth Strategies

An Evolving Workplace Demands Evolving Strategies Look, careers ain't what they used to be—and they shouldn't be. Today’s world is flipping the script on how we work, and Dr. Brandi R. Muñoz is rewriting the book on career development with her SPECS framework. The guy clinging to his outdated Rolodex for advice isn't gonna cut it anymore. "Who Are Your SPECS?...

Bird-X Welcomes Doolittle to Elevate Sales Strategy

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Goodal Skincare Capitalizes on K-Beauty Craze at Costco

A Venture into American Retail Goodal, the darling of Korea's skincare scene, is staking its claim at Costco. This is no small feat, my friends. We're talkin' about a brand that's carved out a sweet niche with its Green Tangerine line. Now it's hitching its wagon to one of America's retail behemoths, known for its unique knack in beauty products. From Olive Young to...

DUPR Teams Up with InBody to Elevate Pickleball Fitness

Well, here's a twist in the pickleball world—DUPR and InBody have struck a deal to bring top-notch body composition tech to the ever-expanding universe of pickleballers. They're merging power players from two different worlds to tap into your performance on the court and your wellness off it. Maybe I'm just jaded from too many marketing pitches, but this one could...

PG&E's $2B Delay: A Blame Game or Real Crisis?

Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...

Telemed Sites Need Solid Payment Systems with AI

Brace for Impact: Payment Processors in Telehealth A new era is brewing in telehealth, with AI coding tools making website creation a breeze for healthcare folks. But here's the kicker: accepting credit cards is not as easy as setting up a snazzy booking page. Take it from Organic Payment Gateways in good ol' Scarborough, Maine, who've decided to toss their hat into this...

Luxury Vinyl Tiles Market Set for Steady Growth to 2031

Luxury Vinyl Tiles: A Market on the Rise Well, folks, the flooring game is picking up steam, and luxury vinyl tiles (LVT) are in the spotlight. With consumers and businesses all looking for something durable yet easy on the eyes and wallet, LVT is answering the call. MarketsandMarkets™ reports that this sector is expected to balloon from USD 18.22 billion in 2026 to USD...

Bright Minds in Hot Water: Investigation Shakes Investors

FDA Throws Wrench Into Bright Minds' Plans This ain't the first time a biotech company's dream has hit the skids, but Bright Minds Biosciences (NASDAQ:DRUG) found themselves in the meat grinder when the FDA threw their epilepsy trial plans under the bus. The partial clinical hold wasn't a gentle slap on the wrist, but a gut punch driven by mouse toxicity findings and...

ESAC Redefines Entertainment Centers, Eyes 2027 Trends

A New Era for Family Entertainment Centers Forget the traditional FEC with its solitary rides; the future's all about constructing social destinations that blend immersive storytelling and hybrid offerings. Elephant Sculpture Art Co., Ltd. (ESAC) is at the forefront, drawing from their Shanghai WUNPARK project to reimagine the design of these amusement hubs. Set to engage...

AMETEK Surpasses Q3 2026 Expectations, Raises Outlook

A Banner Quarter for AMETEK Holy smokes, AMETEK has thrown down some numbers for the third quarter of 2026 that would make any seasoned trader sit up and take notice. We’re talking record-breaking across the board: $2.22 billion in sales, marking a whopping 17% increase over last year. Now, that's not just growth—that's rocket fuel. Earnings per share rocketed up with...